Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
that has been jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. Alteogen will receive an upfront payment and is eligible to receive milestone payments upon Daiichi Sankyo's ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...
For example, during the event, AstraZeneca shared promising early data for its oral GLP-1 candidate, AZD5004, and told Fierce ...
The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...
On Tuesday, a number of major players will release their results before the opening bell, including Home Depot (HD), the leading home improvement retailer, and AstraZeneca (AZN), the multinational ...
The company confirmed that Leon Wang, head of its Chinese arm, was being detained while two other executives, as well as two ...
The Philadelphia Phillies recently raised close to $500 million in capital from three new investors, according to two people ...
2d
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback